20896-44-0

Basic information

• Product Name: 2,5-diaminobenzene sulfonamide
• Synonyms: 2,5-diaminobenzene sulfonamide
• CAS NO: 20896-44-0
• Molecular Formula: C₆H₉N₃O₂S
• Molecular Weight: 187.2196
• Product Categories: Nitro / Nitriles
• Mol File: 20896-44-0.mol

Chemical Properties

• Boiling Point: 483.14 °C at 760 mmHg
• Flash Point: 245.994 °C
• Appearance: /
• Density: 1.523 g/cm³
• Storage Temp.: 2-8°C
• PKA: 10.55±0.60(Predicted)
• CAS DataBase Reference: 2,5-diaminobenzene sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-diaminobenzene sulfonamide(20896-44-0)
• EPA Substance Registry System: 2,5-diaminobenzene sulfonamide(20896-44-0)

Safety Data

• Hazardous Substances Data: 20896-44-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,5-Diaminobenzene sulfonamide is used as an active pharmaceutical ingredient for the treatment of bacterial infections. It is particularly effective against infections in the urinary tract due to its ability to inhibit bacterial growth, thus supporting the body's immune response to clear the infection.
Used in Chemical Production:
Sulfanilamide is utilized as a key intermediate in the synthesis of various dyes, drugs, and pesticides. Its versatility in chemical reactions makes it a crucial component in the production of a wide range of chemical products, contributing to its widespread use in the chemical industry.
Used in Research and Development:
Due to its antimicrobial properties, 2,5-diaminobenzene sulfonamide is also employed in research settings to study the mechanisms of bacterial resistance and to develop new strategies for combating antibiotic-resistant strains. Its role in scientific investigations aids in advancing our understanding of bacterial infections and their treatment.

Upstream product

• 54734-85-9 2-amino-5-nitrobenzenesulfonamide 
• 1000312-84-4 N-(1,1,3-trioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,2,4]thiadiazin-7-yl)methanesulfonamide 
• 1000313-17-6 2-benzylamino-5-nitro-benzenesulfonamide 
• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 
• 5455-59-4 2-Nitrobenzenesulfonamide 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 96-75-3 2-amino-5-nitro-benzenesulfonic acid 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 96-73-1 2-chloro-5-nitro-benzenesulfonic acid 
• 100-00-5 4-chlorobenzonitrile 
• 5825-62-7 N-(4-nitrophenyl)methanesulfonamide 
• 30693-53-9 2-amino-5-nitrobenzenesulfonic acid sodium salt 

Downstream Products

• 847442-09-5 N-{3-[4-(2-cyclohexylideneethyl)-1-hydroxy-4-methyl-3-oxo-3,4-dihydronaphthalen-2-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide 
• 691361-59-8 (4-amino-3-sulfamoyl-phenyl)carbamic acid tert-butyl ester 
• 909105-14-2 2-amino-4-[(methylsulfonyl)amino]-benzenesulfonamide 
• 1370714-06-9 N-[3-(1-benzyl-1H-indol-3-yl)-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methansulfonamide 
• 1000313-22-3 1-{(3-chloro-4-fluoro-benzyl)-[2-(7-methanesulfonylmethyl-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-1H-pyrrole-2-carboxylic acid allyl ester 
• 1033766-02-7 N-{3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1056901-19-9 N-{3-[5-(S)-(4-fluoro-benzyl)-8-hydroxy-5-methyl-6-oxo-5,6-dihydro-indolizin-7-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1071519-56-6 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6,9-dihydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 
• 1071522-56-9 (1S,2R,3S,4R)-3-{(3-fluoro-4-methylbenzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)acetyl]amino}bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1071519-24-8 (1R,2S,7R,8S)-N-{3-[3-(3-chloro-4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 
• 1071519-17-9 (1R,2S,7R,8S)-N-[3-(3-benzyl-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl]methanesulfonamide 

Relevant articles and documents

Des-A-ring benzothiadiazines: Inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase

In our program to discover non-nucleoside, small molecule inhibitors of genotype 1 HCV polymerase, we investigated a series of promising analogs based on a benzothiadiazine screening hit that contains an ABCD ring system. After demonstrating that a methyl

Efficient large-scale synthesis of 2-amino-5- methanesulfonylaminobenzenesulfonamide

A novel synthesis of 2-amino-5-methanesulfonylaminobenzenesulfonamide is described. This preparation begins with readily available 4-nitroaniline and proceeds through five steps (isolations) in 41% overall yield. The described chemistry is conducted on a 50- to 100-g scale and does not require extractive workup procedures or chromatographic purifications. Copyright Taylor & Francis Group, LLC.

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives

This work presents the first structure-based activity prediction model for benzothiadiazines against various genotypes of HCV NS5b polymerase (1a, 1b and 4).The model is a comprehensive workflow of structure-based field template followed by guided docking. The field template was used as a pre-filter and a tool to provide hits in good orientation and position. It was created based on detailed molecular interaction field analysis which includes Topomer CoMFA, grid independent analysis and Superstar. On the other hand, Guided docking was used as a refinement and assessment tool. It was actively directed by two scores: Moldock score as an interaction descriptor (r2 = 0.65) and a template similarity score as a measure for accurate binding-mode compliance. The docking template was based on energy-based pharmacophore analysis. The whole procedure was formulated and tweaked for both screening (ROC of AUC = 0.91) and activity prediction (r2 of 0.8) for the genotype 1a. In order to widen the model scope, linear interaction energy was used as a tool for predicting activities of other genotypes based on the docked ligand poses while mutation binding energy was used to investigate the effect of each amino acid mutation in genotype 4. The model was applied for structure-based fragment hopping by screening a library designed by reaction enumeration. A top scoring hit was used to generate a focused library such that it has lower TPSA than the original class ligands and thus better pharmacokinetic properties. After that, experimental validation was carried out by the synthesis of this library and its biological evaluation which yielded compounds that exhibit EC50 ranging from 1.86 to 23 μM.

A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS

The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-l,4-dihydro-lλ6- benzo[l,2,4]thiadiazin-7-yl} -methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.

4-Hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS

The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.